Heart Drug NP1 Shows Promise in Kidney Repair Research

Research from the University of California, Los Angeles (UCLA) has identified a heart drug known as NP1 that shows promise in repairing damaged kidneys. The study, published in the journal Cell Stem Cell, found that NP1 improves kidney repair and reduces scarring in mice by blocking the protein ENPP1, which is a major obstacle to kidney regeneration.

Senior author Dr. Arjun Deb, a professor of medicine and molecular cell development biology at UCLA, noted that ENPP1 production is elevated in damaged kidneys, disrupting the body's natural healing process.

The research involved inducing kidney injury in mice and demonstrated that those treated with NP1 showed quicker recovery and lower levels of kidney damage markers. The U.S.

Food and Drug Administration (FDA) has already approved NP1 for Phase 1 clinical trials for heart disease, with hopes to expand its application to kidney disease. Further studies are needed to determine the drug's effectiveness in humans, but the findings suggest a new strategy for treating acute kidney injury and potentially slowing chronic kidney disease progression.